Litwin Christine M
Department of Pathology, University of Utah School of Medicine, Salt Lake City 84112, USA.
J Immunotoxicol. 2007 Jul;4(3):219-24. doi: 10.1080/15476910701385646.
The QuantiFERON-TB Gold (QFT-G) is a new FDA approved test for diagnosing Mycobacterium tuberculosis infection. This test detects the release of interferon-gamma (IFNgamma) in whole blood from sensitized persons when it is incubated with mixtures of synthetic peptides representing 2 proteins present in M. tuberculosis: early secretory antigenic target-6 (ESAT-6) and culture filtrate protein-10 (CFP-10). These antigens have greater specificity than tests using purified protein derivative (PPD) as the tuberculosis antigen. The CDC recommends that QFT-G may be used in all circumstances in which the TB skin test is currently used, including contact investigations, evaluation of recent immigrants, and sequential-testing surveillance programs for infection control (e.g., those for health-care workers). Advantages of the QFT-G include: no false-positive reactions from previous BCG vaccination; no cross-reactivity with non-tuberculous mycobacterium infections; and, better detection of active tuberculosis.
结核感染QuantiFERON检测（QFT-G）是一种新的经美国食品药品监督管理局（FDA）批准用于诊断结核分枝杆菌感染的检测方法。该检测通过将全血与代表结核分枝杆菌中存在的2种蛋白质的合成肽混合物孵育，检测致敏个体全血中γ干扰素（IFNγ）的释放。这2种蛋白质分别是早期分泌性抗原靶标6（ESAT-6）和培养滤液蛋白10（CFP-10）。与使用纯化蛋白衍生物（PPD）作为结核抗原的检测相比，这些抗原具有更高的特异性。美国疾病控制与预防中心（CDC）建议，在目前使用结核菌素皮肤试验的所有情况下均可使用QFT-G，包括接触者调查、近期移民评估以及用于感染控制的序贯检测监测项目（如医护人员的监测项目）。QFT-G的优点包括：既往卡介苗接种不会产生假阳性反应；与非结核分枝杆菌感染无交叉反应；能更好地检测活动性结核病。
